Research programme: oral anticancer drugs - Athenex

Drug Profile

Research programme: oral anticancer drugs - Athenex

Alternative Names: oral anticancer drugs + apigenin flavonoid dimer - Athenex

Latest Information Update: 06 Jan 2016

Price : $50

At a glance

  • Originator Kinex Pharmaceuticals
  • Developer Hong Kong Polytechnic University; McGill University
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 13 Feb 2015 Early research in Cancer in Hong Kong (PO)
  • 13 Feb 2015 Kinex in-licenses apigenin flavonoid dimer technology from the Hong Kong University and McGill University
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top